Stockscreener 앱 받기
8.06
0.75%
0.06
시간 외 거래:
8.15
0.09
+1.12%
전일 마감가:
$8.00
열려 있는:
$8
하루 거래량:
1.12M
Relative Volume:
0.66
시가총액:
$2.53B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-11.84
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+1.13%
1개월 성능:
+0.12%
6개월 성능:
-7.14%
1년 성능:
+9.21%
1일 변동 폭
$7.97
$8.135
1주일 범위
$7.79
$8.135
52주 변동 폭
$6.50
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.06 | 2.51B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
152.12 | 68.04B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.48 | 46.30B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.88 | 44.25B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.54 | 18.73B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.50 | 13.82B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia
What drives Amneal Pharmaceuticals Inc. stock pricePhenomenal capital gains - PrintWeekIndia
Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN
Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria
What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal seeks to borrow $1.8 billion in new term loans, offers notes - Investing.com India
Amneal reports 3% revenue growth in Q2, advances deleveraging - Investing.com
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - ADVFN Brasil
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Nasdaq
Silicon Valley - FinancialContent
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times
Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.
Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN
Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire
Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports - insights.citeline.com
5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - FinancialContent
Amneal's Xolair Biosimilar Aces Phase 3 Trial, Eyes $3.9B Market Share with Q4 2025 FDA Filing - Stock Titan
Amneal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for AMRX - Nasdaq
Investing in Amneal Pharmaceuticals (NASDAQ:AMRX) three years ago would have delivered you a 157% gain - simplywall.st
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.82%
0.27%
자본화:
|
볼륨(24시간):